We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
29/6/2018 14:54 | Good Luck Hyper | sikhthetech | |
29/6/2018 14:51 | Indeed Hyper ... all the very best to you with your fine venture. HM | hugus maximus | |
29/6/2018 12:56 | Gonna blow... | cantrememberthis2 | |
29/6/2018 12:16 | You'll make a fine job of it. Good luck Hyper. | waterloo01 | |
29/6/2018 11:31 | Got a seller more likely a heavy PI hitting it at every tick upabove 34p... MMs happy to pick up off... Oversold and Bollinger's are tightening... Grossly oversold giving no value to their pipeline just cash in bank... | cantrememberthis2 | |
29/6/2018 10:08 | chart looks primed for upward movement...cash plus other pipeline products should see this recover from here..mm's overshoot and rsi picking moving in right direction. | pre | |
29/6/2018 09:55 | Need seller to be cleared and done... Still lurking | cantrememberthis2 | |
29/6/2018 08:07 | Looks good now overhang cleared these will potentially be over 50p shortly | kirk 6 | |
28/6/2018 20:36 | Summit have approximately £22.5m+ cash in the bank if you take off May and June 2018 expenditure. However, one cannot disregard a Phase 3 Trial and the potential uplift to share price prior to commencement. As for placings etc, I would support placings as we all have done in other stocks. It comes with the territory. OXB paid off handsomely. ANTIBIOTICS are the future bugbear and will need massive boosts in R&D. This could re-rate massively in any antibiotic headaches across the globe. Discuva was a SENSIBLE play and the board knew the Phase 2 DMD was risk based too. Make of that as you wish. I care not, SUMMIT is not a busted flush and I think everyone needs reminding that the share price is barely taking into account their pipeline, Phase 3 Trial, Discuva and DATA from DMD (££ valuable research data). Game on | cantrememberthis2 | |
28/6/2018 20:19 | My average is about 39p made huge profits elsewhere so been looking for a short term home. | kirk 6 | |
28/6/2018 19:51 | Kirk really? You got double my holdings... Your loss here on bid price must be large... Mine is big due to spread. | cantrememberthis2 | |
28/6/2018 19:41 | Holding 130k shares here now bought another 50k today. Will add another 50k tomorrow | kirk 6 | |
28/6/2018 19:26 | Oh I'm sorry nic. I beg your forgiveness my lord. You are my god. I love you. | cantrememberthis2 | |
28/6/2018 19:19 | U r foolish every buyer is matched by a sellerIf you can't fathom that out maybe you shouldn't be investing | nico115 | |
28/6/2018 19:00 | Kirk unlike IMM and FARN we have no chatter or pump and dump crew. So highly unusual that the share price Take No Account of £10m Discuva acquisition or indeed the IPR. Barely factors in £25m cash in the bank with immediate reduction in spend nor the promising pipeline(s). Also a Phase 3 Trial in 6 months.... Whereas IMM and Farn bounced massively to then come down. Holding 62k shares... Its peeps like me who have absorbed the sellers. | cantrememberthis2 | |
28/6/2018 18:27 | These must be due a re rate shortly | kirk 6 | |
28/6/2018 17:04 | There you have it 35p seller... Cleared for take off. Gla | cantrememberthis2 | |
28/6/2018 16:29 | Indeed Chris ... I think you're referring to the DMD pipeline which was seemingly extensive. I've searched for responses from Dame Kay but so far nothing. She must be gutted after 20 years without seemingly anything positive to followup on? Nothing remotely to do with either her SMTC1100 or any sort of utrophin regulation ... all so incredibly tragic. | hugus maximus | |
28/6/2018 15:19 | Chris it's related to DMD...why would they talk about anything else. Strong buy. | cantrememberthis2 | |
28/6/2018 15:17 | Update on Summit website today: On June 27, 2018, Summit announced the top line data from PhaseOut DMD, a Phase 2 proof of concept trial evaluating the small molecule utrophin modulator, ezutromid. A letter to the DMD Community was published and a copy of this can be found below. Edit: Looks pretty final to me not a mention of other drugs in the 'pipeline'. | chrisatrdg | |
28/6/2018 14:12 | Looks good hxxp://marketrealist | cantrememberthis2 | |
28/6/2018 13:34 | damien - yet i have been trading for many, many years - surprised you've even heard of AMI given your newbie status. If you really think that was a buy then more fool you! | wooster4 | |
28/6/2018 13:17 | Well some of s see value here..I've got 62k shares here..with only 82m shares that's a fair whack. Will keep loading...as below cash and IPR value | cantrememberthis2 | |
28/6/2018 13:05 | Who cares? Well people who bought would care. Is that difficult to understand? who cares if you are steering clear? Maybe it's good that you stay clear, but most do not care what you or anyone else do, in reality. | deadly heisenberg |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions